OncoMatch/Clinical Trials/NCT06350825

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Is NCT06350825 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies ADT+second-generation antiandrogens ± chemotherapy for metastatic prostate cancer.

Phase 3RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06350825Data as of May 2026

Treatment: ADT+second-generation antiandrogens ± chemotherapy — To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis)

Prior therapy

Cannot have received: local treatment (prostate radiotherapy, cryotherapy)

Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.); History of prior local treatment for prostate cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify